Compare WYNN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYNN | PRAX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.3B |
| IPO Year | 2002 | 2020 |
| Metric | WYNN | PRAX |
|---|---|---|
| Price | $81.28 | $281.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | $142.73 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.8M | 356.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $6,717,660,000.00 | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $4.58 | $7,758.26 |
| P/E Ratio | $33.98 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $77.06 | $50.23 |
| 52 Week High | $134.72 | $392.70 |
| Indicator | WYNN | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 27.48 | 26.03 |
| Support Level | N/A | $269.44 |
| Resistance Level | $107.47 | $331.21 |
| Average True Range (ATR) | 2.38 | 15.24 |
| MACD | -0.40 | -5.85 |
| Stochastic Oscillator | 27.34 | 6.71 |
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.